异甘草酸镁针剂联合恩替卡韦治疗慢性乙型肝炎肝硬化的效果及对肝功能的影响  

Effect of magnesium isoglycyrrhizinate injection combined with entecavir on chronic hepatitis B patients with cirrhosis and its influence on liver function

作　　者：杨记康 刘静静 郭舒凯 陈利米 Yang Jikang;Liu Jingjing;Guo Shukai;Chen Limi(Department of Infectious Diseases,Jiaozuo People’s Hospital,Jiaozuo 454000,China)

机构地区：[1]焦作市人民医院感染性疾病科,焦作454000

出　　处：《中国实用医刊》2025年第1期95-98,共4页Chinese Journal of Practical Medicine

摘　　要：目的分析异甘草酸镁针剂联合恩替卡韦治疗慢性乙型肝炎肝硬化的效果及对患者肝功能的影响。方法队列研究。抽取2021年1月至2023年1月焦作市人民医院收治的慢性乙型肝炎肝硬化患者50例,按随机数字表法分为参照组和研究组,每组25例。参照组采用恩替卡韦抗病毒治疗,研究组采用异甘草酸镁针剂联合恩替卡韦抗病毒治疗。比较两组乙型肝炎e抗原(HBeAg)转阴率、肝功能[天冬氨酸转氨酶(AST)、总胆红素(TBIL)、丙氨酸转氨酶(ALT)]、炎症因子[白细胞介素-17(IL-17)、白细胞介素-10(IL-10)]水平、可溶性粘附分子-1(sICAM-1)、巨噬细胞移动抑制因子(MIF)、可溶性细胞凋亡因子(sFas)及不良反应发生率。结果研究组HBeAg转阴率(76.00%,19/25)高于参照组(48.00%,12/25),P<0.05。治疗后,研究组AST、TBIL、ALT、IL-17、IL-10水平低于参照组(P<0.05)。治疗后,研究组sICAM-1、MIF、sFas水平低于参照组(P<0.05)。参照组不良反应发生率(20.00%,5/25)与研究组(12.00%,3/25)比较差异未见统计学意义(P>0.05)。结论对慢性乙型肝炎肝硬化患者采用异甘草酸镁针剂联合恩替卡韦抗病毒治疗,能降低sICAM-1、MIF、sFas水平,减轻炎症反应,提高HBeAg转阴率,改善肝功能,且安全性良好。ObjectiveTo analyze the effect of magnesium isoglycyrrhizinate injection combined with entecavir on chronic hepatitis B patients with cirrhosis,and to investigate its influence on liver function.MethodsFifty chronic hepatitis B patients with cirrhosis treated in Jiaozuo People’s Hospital from January 2021 to January 2023 were selected for the cohort study.And they were divided into a reference group and a study group using a random number table method,with 25 cases in each group.The reference group was treated with entecavir antiviral therapy,and the study group was treated with magnesium isogyrrhizinate injection based the treatment of the reference group.The negative conversion rate of hepatitis B e antigen(HBeAg),liver function assessed by aspartate transferase(AST),total bilirubin(TBIL)and alanine transaminase(ALT),levels of inflammatory factors including interleukin-17(IL-17)and interleukin-10(interleukin-10),soluble adhesion molecules-1(sICAM-1),macrophage migration inhibition factor(MIF),soluble apoptosis factor(sFas)and incidence of adverse reactions were compared between the two groups.ResultsThe negative conversion rate of HBeAg in the study group(76.00%,19/25)was higher than that in the reference group(48.00%,12/25),P<0.05.After treatment,the levels of AST,TBIL,ALT,IL-17 and IL-10 in the study group were lower than those in the reference group(P<0.05).After treatment,the levels of sICAM-1,MIF and sFas in the study group were lower than those in the reference group(P<0.05).There was no significant difference in the incidence of adverse reactions between the reference group(20.00%,5/25)and the study group(12.00%,3/25),P>0.05.ConclusionsMagnesium isoglycyrrhizinate injection combined with entecavir antiviral therapy for chronic hepatitis B patients with cirrhosis can reduce the levels of sICAM-1,MIF,and sFas,attenuate the inflammatory response,increase the negative conversion rate of HBeAg,and improve liver function,with great safety.

关 键 词：恩替卡韦 异甘草酸镁针剂 慢性乙型肝炎肝硬化 

分 类 号：R51[医药卫生—内科学]